Type 1 diabetes: Chronic progressive autoimmune disease

Li Zhang, Roberto Gianani, Maki Nakayama, Edwin Liu, Masakazu Kobayashi, Erin Baschal, Liping Yu, Sunanda Babu, Abby Dawson, Kelly Johnson, Mohamed Jahromi, Theresa Aly, Pamela Fain, Jennifer Barker, Marian Rewers, George S. Eisenbarth

Research output: Chapter in Book/Report/Conference proceedingConference contribution

19 Citations (Scopus)

Abstract

A wealth of data in animal models indicates that type 1A diabetes results from T cell-mediated specific destruction of islet β cells. There is evidence for the NOD mouse model that insulin is the primary autoantigen and a specific insulin peptide B:9-23 is central to pathogenesis. It is also now possible to predict the development of type 1A (immune mediated) diabetes for the great majority of individuals with a combination of genetic, immunological and metabolic parameters. Such prediction is possible because of the chronic nature of the autoimmunity and loss of β cell function that precedes the disease. Given the ability to predict type 1A diabetes trials at all stages of the disorder to prevent β cell destruction are now possible.

Original languageEnglish
Title of host publicationDefining Optimal Immunotherapies for Type 1 Diabetes
Pages85-94
Number of pages10
Publication statusPublished - 21 Nov 2008

Publication series

NameNovartis Foundation Symposium
Volume292
ISSN (Print)1528-2511

Fingerprint Dive into the research topics of 'Type 1 diabetes: Chronic progressive autoimmune disease'. Together they form a unique fingerprint.

  • Cite this

    Zhang, L., Gianani, R., Nakayama, M., Liu, E., Kobayashi, M., Baschal, E., Yu, L., Babu, S., Dawson, A., Johnson, K., Jahromi, M., Aly, T., Fain, P., Barker, J., Rewers, M., & Eisenbarth, G. S. (2008). Type 1 diabetes: Chronic progressive autoimmune disease. In Defining Optimal Immunotherapies for Type 1 Diabetes (pp. 85-94). (Novartis Foundation Symposium; Vol. 292).